These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15261567)

  • 1. New immunosuppressants with potential implication in multiple sclerosis.
    Gonsette RE
    J Neurol Sci; 2004 Aug; 223(1):87-93. PubMed ID: 15261567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
    Gonsette RE; Dubois B
    J Neurol Sci; 2004 Aug; 223(1):81-6. PubMed ID: 15261566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of mitoxantrone in multiple sclerosis--what is known?
    Neuhaus O; Kieseier BC; Hartung HP
    J Neurol Sci; 2004 Aug; 223(1):25-7. PubMed ID: 15261556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potassium channels as therapeutic targets for autoimmune disorders.
    Wulff H; Beeton C; Chandy KG
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis.
    't Hart BA; Hintzen RQ; Laman JD
    Neurodegener Dis; 2008; 5(1):38-52. PubMed ID: 18075274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the tetraspanin CD81 blocks monocyte transmigration and ameliorates EAE.
    Dijkstra S; Kooij G; Verbeek R; van der Pol SM; Amor S; Geisert EE; Dijkstra CD; van Noort JM; Vries HE
    Neurobiol Dis; 2008 Sep; 31(3):413-21. PubMed ID: 18586096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
    Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunopathogenesis and immunotherapy of multiple sclerosis.
    Hemmer B; Nessler S; Zhou D; Kieseier B; Hartung HP
    Nat Clin Pract Neurol; 2006 Apr; 2(4):201-11. PubMed ID: 16932551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic approaches in multiple sclerosis.
    Adorini L
    J Neurol Sci; 2004 Aug; 223(1):13-24. PubMed ID: 15261555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.
    Cavaletti G; Cavalletti E; Crippa L; Di Luccio E; Oggioni N; Mazzanti B; Biagioli T; Sala F; Sala V; Frigo M; Rota S; Tagliabue E; Stanzani L; Galbiati S; Rigolio R; Zoia C; Tredici G; Perseghin P; Dassi M; Riccio P; Lolli F
    J Neuroimmunol; 2004 Jun; 151(1-2):55-65. PubMed ID: 15145604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
    Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
    Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kv1.3 potassium channels as a therapeutic target in multiple sclerosis.
    Rangaraju S; Chi V; Pennington MW; Chandy KG
    Expert Opin Ther Targets; 2009 Aug; 13(8):909-24. PubMed ID: 19538097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitoxantrone does not restore the impaired suppressive function of natural regulatory T cells in patients suffering from multiple sclerosis. A longitudinal ex vivo and in vitro study.
    Putzki N; Kumar M; Kreuzfelder E; Grosse-Wilde H; Diener HC; Limmroth V
    Eur Neurol; 2009; 61(1):27-32. PubMed ID: 18948697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.
    Steinman L; Zamvil SS
    Trends Immunol; 2005 Nov; 26(11):565-71. PubMed ID: 16153891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?
    Johnson AJ; Suidan GL; McDole J; Pirko I
    Int Rev Neurobiol; 2007; 79():73-97. PubMed ID: 17531838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pixantrone on immune-cell function in the course of acute rat experimental allergic encephalomyelitis.
    Mazzanti B; Biagioli T; Aldinucci A; Cavaletti G; Cavalletti E; Oggioni N; Frigo M; Rota S; Tagliabue E; Ballerini C; Massacesi L; Riccio P; Lolli F
    J Neuroimmunol; 2005 Nov; 168(1-2):111-7. PubMed ID: 16120465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glatiramer acetate: mechanisms of action in multiple sclerosis.
    Ziemssen T; Schrempf W
    Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of immunosuppressive agents and particularly of cyclophosphamide on lymphocytes subsets in treated multiple sclerosis patients.
    Gonsette RE; Defalque A; Demonty L
    Riv Neurol; 1987; 57(3):181-4. PubMed ID: 2960008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug insight: using monoclonal antibodies to treat multiple sclerosis.
    Hohlfeld R; Wekerle H
    Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and development of new therapeutics for multiple sclerosis.
    Linker RA; Kieseier BC; Gold R
    Trends Pharmacol Sci; 2008 Nov; 29(11):558-65. PubMed ID: 18804288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.